Intranasal human growth hormone (hGH) induces IGF-I levels comparable to subcutaneous injection with lower systemic exposure to hGH in healthy volunteers.

Abstract

The development of an improved, efficacious hGH product administered by a non-injectable route of delivery such as the nasal route is highly desirable. We have developed a novel nasal hGH product (CP024) that showed excellent nasal absorption in animal models, however translation of these results into the clinical setting is essential, as past attempts to develop such formulations by other groups have been unable to induce IGF-1 in man.